Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR5906] to CD19 (HRP)
- Suitable for: IHC-P, WB
- Reacts with: Human
- Conjugation: HRP
Product nameAnti-CD19 antibody [EPR5906] (HRP)
See all CD19 primary antibodies
DescriptionRabbit monoclonal [EPR5906] to CD19 (HRP)
Tested applicationsSuitable for: IHC-P, WBmore details
Species reactivityReacts with: Human
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human CD19 aa 300 to the C-terminus.
- WB: Ramos whole cell lysate. IHC-P: Normal human tonsil tissue.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab195896 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ab199507 - Rabbit monoclonal IgG (HRP), is suitable for use an as isotype control with this antibody.
|WB||1/5000. Detects a band of approximately 85 kDa (predicted molecular weight: 61 kDa).|
FunctionAssembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Involvement in diseaseDefects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
Sequence similaritiesContains 2 Ig-like C2-type (immunoglobulin-like) domains.
modificationsPhosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation.
- Information by UniProt
- Antibody deficiency due to defect in CD19 antibody
- Antibody deficiency due to defect in CD19, included antibody
- AW495831 antibody
IHC image of CD19 staining in a section of formalin-fixed paraffin-embedded normal human tonsil*, performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab195896, 1/50 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
Anti-CD19 antibody [EPR5906] (HRP) (ab195896) at 1/5000 dilution + Ramos (Human Burkitt's lymphoma cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 61 kDa
Observed band size: 85 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab195896 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab195896 has not yet been referenced specifically in any publications.